 John Kinsella
Concepts (659)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nitric Oxide | 88 | 2023 | 892 | 7.740 |
Why?
| | Hernias, Diaphragmatic, Congenital | 26 | 2024 | 204 | 6.420 |
Why?
| | Persistent Fetal Circulation Syndrome | 37 | 2023 | 137 | 5.160 |
Why?
| | Respiratory Insufficiency | 29 | 2023 | 316 | 3.500 |
Why?
| | Hypertension, Pulmonary | 45 | 2023 | 1876 | 3.480 |
Why?
| | Extracorporeal Membrane Oxygenation | 30 | 2024 | 281 | 3.360 |
Why?
| | Bronchopulmonary Dysplasia | 18 | 2024 | 383 | 2.630 |
Why?
| | Administration, Inhalation | 70 | 2023 | 675 | 2.490 |
Why?
| | Infant, Newborn | 106 | 2024 | 5704 | 2.290 |
Why?
| | Infant, Premature | 31 | 2024 | 540 | 1.930 |
Why?
| | High-Frequency Ventilation | 20 | 2006 | 45 | 1.830 |
Why?
| | Hemodynamics | 40 | 2022 | 1095 | 1.820 |
Why?
| | Bronchodilator Agents | 12 | 2020 | 252 | 1.780 |
Why?
| | Vasodilator Agents | 15 | 2022 | 325 | 1.700 |
Why?
| | Respiratory Distress Syndrome, Newborn | 13 | 2011 | 105 | 1.690 |
Why?
| | Oxygen Inhalation Therapy | 10 | 2015 | 146 | 1.640 |
Why?
| | Pulmonary Circulation | 31 | 2006 | 429 | 1.440 |
Why?
| | Hernia, Diaphragmatic | 9 | 2021 | 69 | 1.420 |
Why?
| | Infant, Premature, Diseases | 6 | 2019 | 95 | 1.310 |
Why?
| | Ventricular Dysfunction, Left | 4 | 2022 | 387 | 1.250 |
Why?
| | Respiration, Artificial | 25 | 2019 | 594 | 1.130 |
Why?
| | Hypoxia | 19 | 2021 | 1070 | 1.060 |
Why?
| | Oxygen | 21 | 2021 | 912 | 0.990 |
Why?
| | Vascular Resistance | 29 | 2021 | 373 | 0.950 |
Why?
| | Echocardiography | 13 | 2023 | 634 | 0.900 |
Why?
| | Blood Gas Analysis | 7 | 2021 | 71 | 0.860 |
Why?
| | Humans | 165 | 2024 | 128896 | 0.850 |
Why?
| | Gestational Age | 22 | 2024 | 857 | 0.840 |
Why?
| | Lung | 33 | 2023 | 3925 | 0.840 |
Why?
| | Transportation of Patients | 3 | 2020 | 50 | 0.820 |
Why?
| | Propofol | 5 | 2024 | 55 | 0.770 |
Why?
| | Bronchoconstriction | 1 | 2020 | 33 | 0.700 |
Why?
| | Sheep | 40 | 2007 | 832 | 0.670 |
Why?
| | Ventricular Dysfunction | 1 | 2019 | 15 | 0.670 |
Why?
| | Pulmonary Gas Exchange | 11 | 2009 | 119 | 0.660 |
Why?
| | Critical Care | 6 | 2013 | 547 | 0.660 |
Why?
| | Pre-Eclampsia | 2 | 2024 | 183 | 0.640 |
Why?
| | Heart Atria | 1 | 2020 | 126 | 0.640 |
Why?
| | Fetus | 21 | 2018 | 764 | 0.630 |
Why?
| | Cardiovascular System | 1 | 2020 | 138 | 0.620 |
Why?
| | Vasodilation | 20 | 2005 | 480 | 0.620 |
Why?
| | Ductus Arteriosus, Patent | 4 | 2015 | 50 | 0.620 |
Why?
| | Infant | 35 | 2024 | 8994 | 0.610 |
Why?
| | Anaphylaxis | 1 | 2020 | 161 | 0.570 |
Why?
| | Trachea | 2 | 2018 | 228 | 0.570 |
Why?
| | Heart Ventricles | 3 | 2020 | 778 | 0.550 |
Why?
| | Early Medical Intervention | 2 | 2014 | 59 | 0.550 |
Why?
| | Anesthetics, Intravenous | 4 | 2024 | 39 | 0.540 |
Why?
| | Pulmonary Surfactants | 6 | 2021 | 108 | 0.530 |
Why?
| | Animals, Newborn | 18 | 2007 | 813 | 0.530 |
Why?
| | Monitoring, Physiologic | 3 | 2019 | 265 | 0.520 |
Why?
| | Prenatal Diagnosis | 1 | 2018 | 189 | 0.520 |
Why?
| | Endothelium-Dependent Relaxing Factors | 1 | 2015 | 17 | 0.510 |
Why?
| | Hyaline Membrane Disease | 6 | 1998 | 20 | 0.510 |
Why?
| | Blood Coagulation | 1 | 2017 | 228 | 0.500 |
Why?
| | Severity of Illness Index | 13 | 2024 | 2767 | 0.500 |
Why?
| | Intensive Care Units | 4 | 2018 | 730 | 0.490 |
Why?
| | Pulmonary Artery | 20 | 2021 | 1091 | 0.490 |
Why?
| | Umbilical Arteries | 1 | 2015 | 49 | 0.490 |
Why?
| | Radial Artery | 1 | 2015 | 68 | 0.480 |
Why?
| | Female | 76 | 2024 | 68162 | 0.470 |
Why?
| | Vitamin A | 1 | 2013 | 55 | 0.440 |
Why?
| | Superoxide Dismutase | 2 | 2006 | 328 | 0.430 |
Why?
| | Practice Guidelines as Topic | 3 | 2020 | 1523 | 0.430 |
Why?
| | Oxygen Consumption | 3 | 2015 | 676 | 0.430 |
Why?
| | Male | 59 | 2024 | 63146 | 0.410 |
Why?
| | Vitamins | 1 | 2013 | 171 | 0.400 |
Why?
| | Conscious Sedation | 2 | 2010 | 84 | 0.400 |
Why?
| | Hospital Mortality | 4 | 2018 | 853 | 0.390 |
Why?
| | Retrospective Studies | 26 | 2024 | 14546 | 0.380 |
Why?
| | Intestinal Obstruction | 1 | 2012 | 48 | 0.380 |
Why?
| | Alcohol-Related Disorders | 1 | 2013 | 114 | 0.380 |
Why?
| | Phosphodiesterase Inhibitors | 5 | 2013 | 85 | 0.380 |
Why?
| | Anesthesia, General | 2 | 2005 | 53 | 0.370 |
Why?
| | Muscle, Smooth, Vascular | 8 | 2005 | 430 | 0.370 |
Why?
| | Lung Diseases | 6 | 2010 | 755 | 0.340 |
Why?
| | Paresis | 1 | 2010 | 30 | 0.340 |
Why?
| | Emergency Medicine | 1 | 2013 | 228 | 0.330 |
Why?
| | Sulfones | 4 | 2013 | 107 | 0.330 |
Why?
| | Dietary Supplements | 1 | 2013 | 533 | 0.330 |
Why?
| | Adrenal Insufficiency | 1 | 2010 | 31 | 0.330 |
Why?
| | Treatment Outcome | 25 | 2024 | 10239 | 0.320 |
Why?
| | Nitric Oxide Synthase | 15 | 2005 | 238 | 0.320 |
Why?
| | Survival Rate | 14 | 2022 | 1884 | 0.320 |
Why?
| | Dipyridamole | 6 | 1998 | 25 | 0.310 |
Why?
| | Herniorrhaphy | 2 | 2020 | 60 | 0.310 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2010 | 187 | 0.300 |
Why?
| | Pacemaker, Artificial | 1 | 2009 | 115 | 0.300 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2011 | 226 | 0.300 |
Why?
| | Nose | 2 | 2008 | 64 | 0.300 |
Why?
| | Heart Defects, Congenital | 7 | 2022 | 752 | 0.300 |
Why?
| | Meconium Aspiration Syndrome | 3 | 2003 | 11 | 0.290 |
Why?
| | Fluorocarbons | 2 | 1999 | 109 | 0.280 |
Why?
| | Cardiac Output | 8 | 2009 | 157 | 0.280 |
Why?
| | Anticoagulants | 2 | 2024 | 622 | 0.270 |
Why?
| | Magnetic Resonance Imaging | 2 | 2019 | 3348 | 0.270 |
Why?
| | Foreign Bodies | 1 | 2008 | 102 | 0.270 |
Why?
| | Action Potentials | 1 | 2010 | 463 | 0.270 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2007 | 128 | 0.270 |
Why?
| | Pregnancy | 19 | 2024 | 6247 | 0.260 |
Why?
| | Animals | 60 | 2022 | 34628 | 0.260 |
Why?
| | Thyroidectomy | 2 | 2024 | 88 | 0.250 |
Why?
| | Child | 21 | 2022 | 20824 | 0.250 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2013 | 985 | 0.240 |
Why?
| | Piperazines | 3 | 2013 | 326 | 0.240 |
Why?
| | Respiration Disorders | 1 | 2005 | 73 | 0.230 |
Why?
| | Hirudins | 1 | 2024 | 51 | 0.230 |
Why?
| | Neck Pain | 1 | 2024 | 26 | 0.230 |
Why?
| | Respiration | 3 | 2019 | 191 | 0.230 |
Why?
| | Muscle Stretching Exercises | 1 | 2024 | 18 | 0.230 |
Why?
| | Antithrombins | 1 | 2024 | 55 | 0.230 |
Why?
| | Tracheostomy | 2 | 2024 | 119 | 0.230 |
Why?
| | Preoperative Care | 3 | 2017 | 343 | 0.220 |
Why?
| | Postoperative Hemorrhage | 1 | 2024 | 85 | 0.220 |
Why?
| | Ventricular Function, Left | 6 | 2020 | 526 | 0.220 |
Why?
| | Heart | 3 | 2019 | 650 | 0.210 |
Why?
| | Ductus Arteriosus | 11 | 2005 | 72 | 0.210 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2020 | 1968 | 0.210 |
Why?
| | Pulmonary Alveoli | 3 | 2021 | 403 | 0.210 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2024 | 67 | 0.210 |
Why?
| | Heparin | 1 | 2024 | 252 | 0.210 |
Why?
| | Fatal Outcome | 4 | 2012 | 301 | 0.210 |
Why?
| | Nitrites | 1 | 2002 | 81 | 0.200 |
Why?
| | Infant, Very Low Birth Weight | 2 | 2017 | 68 | 0.200 |
Why?
| | Antioxidants | 1 | 2006 | 557 | 0.200 |
Why?
| | Respiratory Therapy | 3 | 2003 | 23 | 0.200 |
Why?
| | Gastroesophageal Reflux | 2 | 2022 | 240 | 0.200 |
Why?
| | Prospective Studies | 10 | 2023 | 7060 | 0.190 |
Why?
| | Incidence | 5 | 2015 | 2634 | 0.190 |
Why?
| | Precision Medicine | 2 | 2023 | 385 | 0.180 |
Why?
| | Water-Electrolyte Imbalance | 1 | 2001 | 40 | 0.180 |
Why?
| | Risk Factors | 11 | 2024 | 9792 | 0.180 |
Why?
| | Vasoconstriction | 3 | 2005 | 195 | 0.180 |
Why?
| | Neuromuscular Nondepolarizing Agents | 1 | 2020 | 13 | 0.180 |
Why?
| | Emergency Treatment | 1 | 2002 | 116 | 0.180 |
Why?
| | Plethysmography | 1 | 2001 | 109 | 0.180 |
Why?
| | Peptide Fragments | 1 | 2024 | 694 | 0.180 |
Why?
| | Fundoplication | 1 | 2020 | 54 | 0.180 |
Why?
| | Respiratory Function Tests | 5 | 2019 | 596 | 0.170 |
Why?
| | Postoperative Complications | 6 | 2017 | 2494 | 0.170 |
Why?
| | Papio | 6 | 1995 | 97 | 0.170 |
Why?
| | Randomized Controlled Trials as Topic | 6 | 2019 | 1366 | 0.170 |
Why?
| | Carbon Monoxide | 1 | 2000 | 68 | 0.170 |
Why?
| | Fluid Therapy | 2 | 2011 | 135 | 0.170 |
Why?
| | Therapy, Computer-Assisted | 1 | 2020 | 62 | 0.170 |
Why?
| | Time Factors | 12 | 2017 | 6568 | 0.170 |
Why?
| | Blood Pressure | 13 | 2014 | 1743 | 0.160 |
Why?
| | Patient Care Team | 2 | 2016 | 605 | 0.160 |
Why?
| | Pulmonary Veins | 2 | 1999 | 95 | 0.160 |
Why?
| | Infusions, Intravenous | 4 | 2024 | 395 | 0.160 |
Why?
| | Thrombelastography | 1 | 2020 | 148 | 0.160 |
Why?
| | Neoplasm Staging | 3 | 2018 | 1285 | 0.160 |
Why?
| | Critical Illness | 3 | 2014 | 753 | 0.150 |
Why?
| | Combined Modality Therapy | 7 | 2017 | 1213 | 0.150 |
Why?
| | Blood Coagulation Disorders | 1 | 2020 | 163 | 0.150 |
Why?
| | Treatment Failure | 5 | 2007 | 345 | 0.150 |
Why?
| | Risk | 3 | 2021 | 866 | 0.150 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2018 | 69 | 0.150 |
Why?
| | Single-Blind Method | 2 | 2013 | 273 | 0.140 |
Why?
| | Cerebral Hemorrhage | 2 | 2014 | 108 | 0.140 |
Why?
| | Intubation, Intratracheal | 2 | 2018 | 241 | 0.140 |
Why?
| | Retinopathy of Prematurity | 1 | 2019 | 128 | 0.140 |
Why?
| | Abnormalities, Multiple | 1 | 2019 | 178 | 0.140 |
Why?
| | Heart Rate | 4 | 2009 | 807 | 0.140 |
Why?
| | Pneumonectomy | 1 | 2019 | 150 | 0.140 |
Why?
| | Thiopental | 1 | 1997 | 3 | 0.140 |
Why?
| | Ondansetron | 1 | 1997 | 14 | 0.140 |
Why?
| | Biological Products | 1 | 2000 | 202 | 0.140 |
Why?
| | Methemoglobin | 2 | 1993 | 20 | 0.140 |
Why?
| | Smoke Inhalation Injury | 3 | 1991 | 24 | 0.140 |
Why?
| | Dyspnea | 1 | 2018 | 236 | 0.140 |
Why?
| | Follow-Up Studies | 10 | 2019 | 4917 | 0.140 |
Why?
| | Emergency Service, Hospital | 1 | 2008 | 1977 | 0.130 |
Why?
| | Blood Circulation | 3 | 1998 | 41 | 0.130 |
Why?
| | Pulmonary Edema | 1 | 1997 | 105 | 0.130 |
Why?
| | Anesthesia, Local | 1 | 2016 | 17 | 0.130 |
Why?
| | Antiemetics | 1 | 1997 | 38 | 0.130 |
Why?
| | Capillary Permeability | 1 | 1997 | 141 | 0.130 |
Why?
| | Glycocalyx | 1 | 2016 | 22 | 0.130 |
Why?
| | Mentors | 1 | 2018 | 174 | 0.130 |
Why?
| | Guidelines as Topic | 1 | 2018 | 259 | 0.130 |
Why?
| | Estradiol | 4 | 2001 | 494 | 0.130 |
Why?
| | Child, Preschool | 14 | 2017 | 10457 | 0.130 |
Why?
| | Infant, Newborn, Diseases | 2 | 2014 | 108 | 0.130 |
Why?
| | Survivors | 1 | 2019 | 458 | 0.130 |
Why?
| | Receptors, Platelet-Derived Growth Factor | 1 | 1996 | 14 | 0.130 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2019 | 226 | 0.130 |
Why?
| | Echocardiography, Doppler | 2 | 2001 | 111 | 0.130 |
Why?
| | Disease Management | 2 | 2017 | 594 | 0.130 |
Why?
| | Down Syndrome | 1 | 2022 | 454 | 0.130 |
Why?
| | Hypnotics and Sedatives | 2 | 2024 | 158 | 0.130 |
Why?
| | Dimensional Measurement Accuracy | 1 | 2015 | 13 | 0.130 |
Why?
| | Length of Stay | 5 | 2017 | 1126 | 0.130 |
Why?
| | Cardiac Catheterization | 6 | 2022 | 583 | 0.130 |
Why?
| | Nitroarginine | 10 | 2005 | 57 | 0.130 |
Why?
| | Surgical Procedures, Operative | 1 | 2018 | 249 | 0.130 |
Why?
| | Thyroid Carcinoma, Anaplastic | 1 | 2016 | 35 | 0.130 |
Why?
| | Chronic Disease | 8 | 2013 | 1715 | 0.120 |
Why?
| | Academic Medical Centers | 1 | 2018 | 473 | 0.120 |
Why?
| | Evidence-Based Medicine | 1 | 2019 | 729 | 0.120 |
Why?
| | Neutrophils | 3 | 1999 | 1203 | 0.120 |
Why?
| | Prognosis | 6 | 2023 | 3787 | 0.120 |
Why?
| | Cerebrovascular Circulation | 3 | 1995 | 223 | 0.120 |
Why?
| | Faculty, Medical | 1 | 2018 | 263 | 0.120 |
Why?
| | Radiography | 2 | 2008 | 863 | 0.120 |
Why?
| | Middle Aged | 15 | 2019 | 30977 | 0.120 |
Why?
| | United Kingdom | 2 | 2013 | 263 | 0.120 |
Why?
| | Risk Assessment | 4 | 2017 | 3286 | 0.120 |
Why?
| | Sildenafil Citrate | 4 | 2021 | 59 | 0.120 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 311 | 0.120 |
Why?
| | Statistics as Topic | 1 | 2015 | 306 | 0.120 |
Why?
| | Logistic Models | 4 | 2024 | 1963 | 0.110 |
Why?
| | Double-Blind Method | 3 | 2009 | 1858 | 0.110 |
Why?
| | Ventilator Weaning | 2 | 2005 | 35 | 0.110 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2011 | 528 | 0.110 |
Why?
| | Mothers | 1 | 2020 | 723 | 0.110 |
Why?
| | Ammonia | 2 | 1992 | 62 | 0.110 |
Why?
| | Thrombosis | 1 | 2017 | 331 | 0.110 |
Why?
| | Registries | 5 | 2022 | 1916 | 0.110 |
Why?
| | Biomarkers | 4 | 2016 | 3874 | 0.110 |
Why?
| | Vasopressins | 1 | 2014 | 64 | 0.110 |
Why?
| | Pediatrics | 2 | 2019 | 1060 | 0.110 |
Why?
| | Continuity of Patient Care | 1 | 2016 | 278 | 0.110 |
Why?
| | Aged | 12 | 2019 | 22035 | 0.110 |
Why?
| | Vasoconstrictor Agents | 1 | 2014 | 130 | 0.110 |
Why?
| | Clinical Trials as Topic | 3 | 2008 | 1002 | 0.110 |
Why?
| | Elective Surgical Procedures | 2 | 2011 | 164 | 0.110 |
Why?
| | Alcohol Withdrawal Delirium | 1 | 2013 | 7 | 0.110 |
Why?
| | Survival Analysis | 3 | 2009 | 1282 | 0.110 |
Why?
| | Hemorrhage | 1 | 2017 | 658 | 0.100 |
Why?
| | Pilot Projects | 5 | 2024 | 1545 | 0.100 |
Why?
| | Hypotension | 1 | 2014 | 118 | 0.100 |
Why?
| | Epoprostenol | 3 | 2021 | 135 | 0.100 |
Why?
| | Cell Nucleus | 1 | 1996 | 569 | 0.100 |
Why?
| | Critical Care Nursing | 1 | 2013 | 34 | 0.100 |
Why?
| | Cyclic GMP | 4 | 2001 | 85 | 0.100 |
Why?
| | Coronary Circulation | 2 | 1995 | 138 | 0.100 |
Why?
| | Renal Dialysis | 1 | 2016 | 417 | 0.100 |
Why?
| | Diaphragm | 2 | 2023 | 41 | 0.100 |
Why?
| | Liver Cirrhosis | 1 | 2014 | 274 | 0.100 |
Why?
| | Pain, Postoperative | 2 | 2024 | 227 | 0.100 |
Why?
| | Adult | 15 | 2024 | 35361 | 0.100 |
Why?
| | Vascular Diseases | 1 | 2015 | 241 | 0.100 |
Why?
| | Early Diagnosis | 1 | 2013 | 232 | 0.100 |
Why?
| | Catheterization, Swan-Ganz | 1 | 2011 | 8 | 0.090 |
Why?
| | Recombinant Proteins | 2 | 2024 | 1304 | 0.090 |
Why?
| | Delivery Rooms | 1 | 2011 | 7 | 0.090 |
Why?
| | Ventilators, Mechanical | 2 | 2016 | 58 | 0.090 |
Why?
| | Troponin | 1 | 2011 | 50 | 0.090 |
Why?
| | Patient Admission | 1 | 2013 | 185 | 0.090 |
Why?
| | Kidney Tubules | 1 | 1992 | 114 | 0.090 |
Why?
| | Case-Control Studies | 2 | 2018 | 3334 | 0.090 |
Why?
| | Acetylcholine | 5 | 2001 | 185 | 0.090 |
Why?
| | Respiratory Mechanics | 3 | 1999 | 65 | 0.090 |
Why?
| | Diseases in Twins | 1 | 2012 | 174 | 0.090 |
Why?
| | Cardiac Output, Low | 1 | 1991 | 66 | 0.090 |
Why?
| | Death, Sudden, Cardiac | 1 | 2012 | 179 | 0.090 |
Why?
| | Monitoring, Intraoperative | 2 | 2008 | 44 | 0.090 |
Why?
| | Alfentanil | 1 | 2010 | 2 | 0.090 |
Why?
| | Delivery, Obstetric | 1 | 1991 | 133 | 0.090 |
Why?
| | Oocyte Retrieval | 1 | 2010 | 12 | 0.090 |
Why?
| | Disease Models, Animal | 7 | 2007 | 3994 | 0.090 |
Why?
| | DNA-Binding Proteins | 2 | 2007 | 1423 | 0.090 |
Why?
| | Nitric Oxide Synthase Type III | 7 | 2007 | 204 | 0.090 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2011 | 162 | 0.090 |
Why?
| | Vitamin D Deficiency | 1 | 2012 | 179 | 0.090 |
Why?
| | Communication | 1 | 2016 | 839 | 0.090 |
Why?
| | Thermodilution | 2 | 2005 | 14 | 0.080 |
Why?
| | Physicians | 1 | 2018 | 846 | 0.080 |
Why?
| | Endothelium, Vascular | 5 | 2016 | 917 | 0.080 |
Why?
| | Platelet-Derived Growth Factor | 2 | 2003 | 89 | 0.080 |
Why?
| | Abdomen | 1 | 2010 | 116 | 0.080 |
Why?
| | Positive-Pressure Respiration | 2 | 2000 | 75 | 0.080 |
Why?
| | Thoracic Surgical Procedures | 1 | 2010 | 69 | 0.080 |
Why?
| | Airway Obstruction | 1 | 1991 | 157 | 0.080 |
Why?
| | Endothelin Receptor Antagonists | 3 | 1998 | 62 | 0.080 |
Why?
| | Analysis of Variance | 6 | 2014 | 1283 | 0.080 |
Why?
| | Endothelins | 3 | 2000 | 61 | 0.080 |
Why?
| | Cohort Studies | 4 | 2024 | 5394 | 0.080 |
Why?
| | Vitamin D | 1 | 2012 | 384 | 0.080 |
Why?
| | Prostaglandins | 2 | 2001 | 85 | 0.080 |
Why?
| | Hospitalization | 1 | 2018 | 2080 | 0.080 |
Why?
| | Point-of-Care Systems | 1 | 2010 | 149 | 0.070 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2011 | 258 | 0.070 |
Why?
| | Anesthetics, Combined | 1 | 2008 | 8 | 0.070 |
Why?
| | Patient Readmission | 1 | 2013 | 674 | 0.070 |
Why?
| | Regional Blood Flow | 4 | 1998 | 462 | 0.070 |
Why?
| | Chest Wall Oscillation | 1 | 2007 | 4 | 0.070 |
Why?
| | Transcription Factors | 1 | 1996 | 1634 | 0.070 |
Why?
| | Adrenal Cortex Hormones | 1 | 2011 | 525 | 0.070 |
Why?
| | Hydrocortisone | 1 | 2010 | 300 | 0.070 |
Why?
| | Receptors, Endothelin | 3 | 2000 | 50 | 0.070 |
Why?
| | Acute Disease | 2 | 2005 | 978 | 0.070 |
Why?
| | Neoplasms | 2 | 2019 | 2426 | 0.070 |
Why?
| | Lung Neoplasms | 2 | 2019 | 2353 | 0.070 |
Why?
| | Sex Distribution | 1 | 2008 | 357 | 0.070 |
Why?
| | 3',5'-Cyclic-GMP Phosphodiesterases | 2 | 1998 | 17 | 0.070 |
Why?
| | Microspheres | 3 | 1991 | 123 | 0.070 |
Why?
| | Leukomalacia, Periventricular | 1 | 2006 | 7 | 0.070 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 2 | 2004 | 109 | 0.070 |
Why?
| | Purines | 3 | 2013 | 170 | 0.070 |
Why?
| | Piperidines | 1 | 2008 | 186 | 0.060 |
Why?
| | Intracranial Hemorrhages | 1 | 2006 | 77 | 0.060 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2010 | 952 | 0.060 |
Why?
| | Swine | 2 | 2003 | 740 | 0.060 |
Why?
| | Endothelin-1 | 5 | 2000 | 179 | 0.060 |
Why?
| | Methyl Ethers | 1 | 2005 | 8 | 0.060 |
Why?
| | Electroencephalography | 1 | 2008 | 387 | 0.060 |
Why?
| | Atrial Natriuretic Factor | 2 | 1996 | 56 | 0.060 |
Why?
| | Enzyme Inhibitors | 7 | 2005 | 827 | 0.060 |
Why?
| | Cross-Over Studies | 2 | 1998 | 513 | 0.060 |
Why?
| | Anesthetics, Inhalation | 1 | 2005 | 16 | 0.060 |
Why?
| | Lung Compliance | 1 | 2005 | 46 | 0.060 |
Why?
| | Airway Resistance | 1 | 2005 | 38 | 0.060 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2005 | 39 | 0.060 |
Why?
| | Signal Transduction | 3 | 2005 | 4857 | 0.060 |
Why?
| | Longitudinal Studies | 2 | 2006 | 2668 | 0.060 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 271 | 0.060 |
Why?
| | Prenatal Care | 1 | 2007 | 272 | 0.060 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2007 | 245 | 0.060 |
Why?
| | Electric Impedance | 1 | 2005 | 102 | 0.060 |
Why?
| | Aging | 2 | 1992 | 1767 | 0.060 |
Why?
| | Pulmonary Wedge Pressure | 2 | 2022 | 67 | 0.060 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 1967 | 0.060 |
Why?
| | Amides | 1 | 2005 | 91 | 0.060 |
Why?
| | Drug Administration Schedule | 4 | 2011 | 760 | 0.060 |
Why?
| | Rats | 7 | 2005 | 5236 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 1 | 2013 | 1281 | 0.060 |
Why?
| | Carcinoma | 2 | 2016 | 214 | 0.060 |
Why?
| | Carbon Dioxide | 4 | 1999 | 261 | 0.060 |
Why?
| | Home Nursing | 1 | 2003 | 26 | 0.050 |
Why?
| | Bronchoalveolar Lavage | 1 | 2003 | 92 | 0.050 |
Why?
| | Coronary Artery Bypass | 1 | 2005 | 224 | 0.050 |
Why?
| | Colorectal Neoplasms | 1 | 2010 | 730 | 0.050 |
Why?
| | Cost-Benefit Analysis | 3 | 2011 | 615 | 0.050 |
Why?
| | Birth Weight | 1 | 2006 | 493 | 0.050 |
Why?
| | Esophagus | 1 | 2005 | 253 | 0.050 |
Why?
| | Endothelial Growth Factors | 1 | 2002 | 63 | 0.050 |
Why?
| | Analgesics | 1 | 2024 | 165 | 0.050 |
Why?
| | Disability Evaluation | 1 | 2024 | 290 | 0.050 |
Why?
| | Lymphokines | 1 | 2002 | 126 | 0.050 |
Why?
| | Embryonic and Fetal Development | 3 | 2000 | 95 | 0.050 |
Why?
| | Forced Expiratory Volume | 2 | 2016 | 509 | 0.050 |
Why?
| | Intermittent Positive-Pressure Ventilation | 2 | 1993 | 11 | 0.050 |
Why?
| | Surgical Flaps | 1 | 2023 | 140 | 0.050 |
Why?
| | Stomach | 1 | 2002 | 109 | 0.050 |
Why?
| | Mouth Mucosa | 1 | 2022 | 89 | 0.050 |
Why?
| | Mosaicism | 1 | 2022 | 71 | 0.050 |
Why?
| | Sequence Deletion | 1 | 2022 | 180 | 0.050 |
Why?
| | Thyroid Neoplasms | 2 | 2016 | 308 | 0.050 |
Why?
| | Cross-Sectional Studies | 1 | 2013 | 5032 | 0.050 |
Why?
| | Evaluation Studies as Topic | 2 | 1992 | 175 | 0.050 |
Why?
| | Forkhead Transcription Factors | 1 | 2022 | 182 | 0.050 |
Why?
| | Phenotype | 2 | 2023 | 3059 | 0.050 |
Why?
| | APACHE | 1 | 2001 | 65 | 0.050 |
Why?
| | Estrogen Antagonists | 1 | 2001 | 45 | 0.050 |
Why?
| | Uterus | 1 | 2002 | 204 | 0.050 |
Why?
| | Muscle, Smooth | 2 | 2000 | 151 | 0.040 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2002 | 376 | 0.040 |
Why?
| | Milrinone | 1 | 2021 | 29 | 0.040 |
Why?
| | Labor, Obstetric | 1 | 2001 | 55 | 0.040 |
Why?
| | Ligation | 5 | 2002 | 87 | 0.040 |
Why?
| | Calibration | 1 | 2001 | 137 | 0.040 |
Why?
| | Surveys and Questionnaires | 1 | 2013 | 5355 | 0.040 |
Why?
| | Injections, Intra-Arterial | 1 | 2000 | 25 | 0.040 |
Why?
| | Protoporphyrins | 1 | 2000 | 16 | 0.040 |
Why?
| | Self Report | 1 | 2024 | 796 | 0.040 |
Why?
| | Inflammation | 1 | 2010 | 2694 | 0.040 |
Why?
| | Patient Transfer | 1 | 2002 | 162 | 0.040 |
Why?
| | Hydrocarbons, Brominated | 1 | 1999 | 5 | 0.040 |
Why?
| | Adolescent | 8 | 2005 | 20197 | 0.040 |
Why?
| | Observational Studies as Topic | 1 | 2019 | 108 | 0.040 |
Why?
| | Postoperative Period | 2 | 2016 | 319 | 0.040 |
Why?
| | Blotting, Northern | 4 | 2000 | 202 | 0.040 |
Why?
| | Potassium Channel Blockers | 1 | 1999 | 35 | 0.040 |
Why?
| | Esophageal Neoplasms | 1 | 2002 | 297 | 0.040 |
Why?
| | Scotland | 1 | 2018 | 12 | 0.040 |
Why?
| | Angiography | 1 | 1999 | 199 | 0.040 |
Why?
| | Constriction, Pathologic | 1 | 1999 | 230 | 0.040 |
Why?
| | Digestive System Physiological Phenomena | 1 | 1998 | 4 | 0.040 |
Why?
| | Receptors, Estrogen | 1 | 2001 | 423 | 0.040 |
Why?
| | Acidosis | 2 | 1992 | 88 | 0.040 |
Why?
| | Drug Synergism | 2 | 1998 | 354 | 0.040 |
Why?
| | Asphyxia Neonatorum | 1 | 1998 | 17 | 0.040 |
Why?
| | Leukocyte Count | 2 | 1997 | 328 | 0.040 |
Why?
| | Blood Vessels | 1 | 2000 | 184 | 0.040 |
Why?
| | Body Weight | 2 | 2005 | 931 | 0.040 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 1998 | 49 | 0.040 |
Why?
| | Immunohistochemistry | 4 | 2005 | 1694 | 0.040 |
Why?
| | Frontal Bone | 1 | 1997 | 13 | 0.040 |
Why?
| | Receptor, Endothelin A | 4 | 2000 | 62 | 0.040 |
Why?
| | Occipital Bone | 1 | 1997 | 19 | 0.040 |
Why?
| | Disease Progression | 2 | 2017 | 2603 | 0.040 |
Why?
| | Cephalometry | 1 | 1997 | 32 | 0.040 |
Why?
| | Potassium Channels | 1 | 1998 | 139 | 0.040 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2002 | 626 | 0.040 |
Why?
| | Growth | 1 | 1997 | 57 | 0.030 |
Why?
| | Arterial Pressure | 1 | 2017 | 118 | 0.030 |
Why?
| | Syndecan-1 | 1 | 2016 | 27 | 0.030 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2016 | 21 | 0.030 |
Why?
| | Blood Pressure Determination | 1 | 2017 | 150 | 0.030 |
Why?
| | Ventricular Function, Right | 1 | 2019 | 274 | 0.030 |
Why?
| | Molecular Sequence Data | 3 | 1998 | 2842 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 1997 | 173 | 0.030 |
Why?
| | Nausea | 1 | 1997 | 104 | 0.030 |
Why?
| | Expectorants | 1 | 2016 | 24 | 0.030 |
Why?
| | Arteriovenous Shunt, Surgical | 1 | 2016 | 16 | 0.030 |
Why?
| | Kidney | 3 | 1991 | 1330 | 0.030 |
Why?
| | Patient Selection | 1 | 2000 | 671 | 0.030 |
Why?
| | Body Height | 1 | 1997 | 191 | 0.030 |
Why?
| | Endothelin-3 | 1 | 1996 | 3 | 0.030 |
Why?
| | Vascular Patency | 1 | 2016 | 102 | 0.030 |
Why?
| | Clinical Protocols | 1 | 2017 | 255 | 0.030 |
Why?
| | Arginine | 2 | 1994 | 254 | 0.030 |
Why?
| | Ireland | 1 | 2016 | 27 | 0.030 |
Why?
| | Interrupted Time Series Analysis | 1 | 2016 | 52 | 0.030 |
Why?
| | Interferon-Stimulated Gene Factor 3 | 1 | 1996 | 1 | 0.030 |
Why?
| | Rats, Inbred Strains | 3 | 1992 | 365 | 0.030 |
Why?
| | Vomiting | 1 | 1997 | 128 | 0.030 |
Why?
| | Arteriovenous Fistula | 1 | 2016 | 37 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 1996 | 34 | 0.030 |
Why?
| | Gastrostomy | 1 | 1997 | 113 | 0.030 |
Why?
| | Lung Injury | 2 | 2011 | 214 | 0.030 |
Why?
| | Substance Withdrawal Syndrome | 1 | 1998 | 171 | 0.030 |
Why?
| | Stroke Volume | 1 | 2019 | 587 | 0.030 |
Why?
| | Luciferases | 1 | 1996 | 148 | 0.030 |
Why?
| | Algorithms | 2 | 2000 | 1626 | 0.030 |
Why?
| | Steroids | 1 | 2016 | 148 | 0.030 |
Why?
| | Enteral Nutrition | 1 | 1997 | 186 | 0.030 |
Why?
| | Blotting, Western | 3 | 2005 | 1188 | 0.030 |
Why?
| | Genetic Counseling | 1 | 2015 | 72 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 1999 | 1435 | 0.030 |
Why?
| | Age Factors | 2 | 2000 | 3133 | 0.030 |
Why?
| | Genes, Reporter | 1 | 1996 | 268 | 0.030 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2001 | 544 | 0.030 |
Why?
| | Tyrosine | 1 | 1996 | 219 | 0.030 |
Why?
| | Indiana | 1 | 2015 | 33 | 0.030 |
Why?
| | Ventilator-Induced Lung Injury | 1 | 2015 | 57 | 0.030 |
Why?
| | Nitric Oxide Synthase Type II | 3 | 2001 | 172 | 0.030 |
Why?
| | Biological Transport | 3 | 1991 | 394 | 0.030 |
Why?
| | Peptides, Cyclic | 4 | 1998 | 258 | 0.030 |
Why?
| | Aorta | 4 | 1998 | 410 | 0.030 |
Why?
| | Primary Prevention | 1 | 2016 | 191 | 0.030 |
Why?
| | Psychomotor Performance | 1 | 1997 | 310 | 0.030 |
Why?
| | Endothelium | 1 | 1995 | 114 | 0.030 |
Why?
| | Organ Dysfunction Scores | 1 | 2014 | 46 | 0.030 |
Why?
| | Base Sequence | 2 | 1996 | 2157 | 0.030 |
Why?
| | Infant, Low Birth Weight | 1 | 2015 | 134 | 0.030 |
Why?
| | Cardiovascular Agents | 1 | 2015 | 155 | 0.030 |
Why?
| | Vasomotor System | 3 | 2002 | 43 | 0.030 |
Why?
| | Costs and Cost Analysis | 2 | 2009 | 211 | 0.030 |
Why?
| | Life Support Care | 1 | 2014 | 29 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 1996 | 360 | 0.030 |
Why?
| | Schools, Medical | 1 | 2015 | 128 | 0.030 |
Why?
| | Stress, Mechanical | 3 | 2001 | 470 | 0.030 |
Why?
| | Blood Flow Velocity | 2 | 1992 | 413 | 0.030 |
Why?
| | Area Under Curve | 1 | 2014 | 285 | 0.030 |
Why?
| | Drug Evaluation | 1 | 1993 | 79 | 0.030 |
Why?
| | Acute Lung Injury | 1 | 2016 | 278 | 0.030 |
Why?
| | Young Adult | 1 | 2009 | 12286 | 0.030 |
Why?
| | In Vitro Techniques | 2 | 1992 | 1061 | 0.030 |
Why?
| | Reference Values | 3 | 2002 | 791 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 1996 | 640 | 0.030 |
Why?
| | Prevalence | 1 | 2019 | 2540 | 0.030 |
Why?
| | Lung Transplantation | 1 | 2015 | 276 | 0.030 |
Why?
| | Antihypertensive Agents | 1 | 1997 | 487 | 0.030 |
Why?
| | United States | 3 | 2012 | 13975 | 0.030 |
Why?
| | Diagnostic Imaging | 1 | 2015 | 327 | 0.030 |
Why?
| | Hypertension | 1 | 2002 | 1236 | 0.030 |
Why?
| | Decision Making | 1 | 2019 | 837 | 0.030 |
Why?
| | ROC Curve | 1 | 2014 | 500 | 0.030 |
Why?
| | Child Development | 1 | 1997 | 451 | 0.030 |
Why?
| | DNA | 2 | 1998 | 1406 | 0.030 |
Why?
| | Lactic Acid | 1 | 2014 | 296 | 0.030 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2012 | 65 | 0.030 |
Why?
| | Ammonium Chloride | 1 | 1992 | 5 | 0.020 |
Why?
| | Brain Chemistry | 1 | 1992 | 115 | 0.020 |
Why?
| | Nephrons | 1 | 1992 | 17 | 0.020 |
Why?
| | Streptococcus agalactiae | 1 | 1993 | 91 | 0.020 |
Why?
| | Brain | 2 | 1997 | 2592 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2016 | 7050 | 0.020 |
Why?
| | Liver | 1 | 2020 | 1832 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 1995 | 328 | 0.020 |
Why?
| | Isotonic Solutions | 1 | 2011 | 37 | 0.020 |
Why?
| | United States Food and Drug Administration | 1 | 2012 | 204 | 0.020 |
Why?
| | Fetal Diseases | 2 | 2003 | 148 | 0.020 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 2 | 2001 | 73 | 0.020 |
Why?
| | Asthma | 1 | 2005 | 2258 | 0.020 |
Why?
| | Streptococcal Infections | 1 | 1993 | 145 | 0.020 |
Why?
| | Odds Ratio | 1 | 2014 | 1019 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2012 | 193 | 0.020 |
Why?
| | Carboxyhemoglobin | 1 | 1991 | 5 | 0.020 |
Why?
| | Radioisotopes | 1 | 1991 | 31 | 0.020 |
Why?
| | Phosphorylation | 1 | 1996 | 1685 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 1996 | 1194 | 0.020 |
Why?
| | Intensive Care Units, Pediatric | 1 | 1993 | 189 | 0.020 |
Why?
| | Body Constitution | 1 | 1991 | 53 | 0.020 |
Why?
| | RNA, Messenger | 3 | 2007 | 2700 | 0.020 |
Why?
| | Ultrasonography | 1 | 2015 | 727 | 0.020 |
Why?
| | Hypertrophy, Right Ventricular | 2 | 2003 | 145 | 0.020 |
Why?
| | Models, Cardiovascular | 1 | 1992 | 193 | 0.020 |
Why?
| | Echovirus Infections | 1 | 1990 | 1 | 0.020 |
Why?
| | Preoperative Period | 1 | 2010 | 112 | 0.020 |
Why?
| | Enterovirus B, Human | 1 | 1990 | 25 | 0.020 |
Why?
| | Burns | 2 | 1991 | 286 | 0.020 |
Why?
| | Meningoencephalitis | 1 | 1990 | 25 | 0.020 |
Why?
| | Medical Audit | 1 | 2010 | 78 | 0.020 |
Why?
| | Guanidines | 2 | 2001 | 35 | 0.020 |
Why?
| | Neurologic Examination | 1 | 2009 | 113 | 0.020 |
Why?
| | Isoenzymes | 2 | 2001 | 303 | 0.020 |
Why?
| | Cyclooxygenase Inhibitors | 2 | 2001 | 80 | 0.020 |
Why?
| | Hospital Costs | 1 | 2010 | 117 | 0.020 |
Why?
| | Tetraethylammonium | 2 | 1999 | 17 | 0.020 |
Why?
| | 4-Aminopyridine | 2 | 1999 | 23 | 0.020 |
Why?
| | Pressure | 2 | 2002 | 238 | 0.020 |
Why?
| | Constriction | 2 | 1999 | 44 | 0.020 |
Why?
| | Macrophages, Alveolar | 1 | 1991 | 389 | 0.020 |
Why?
| | Immunologic Techniques | 2 | 1999 | 39 | 0.020 |
Why?
| | Heart Diseases | 1 | 1992 | 356 | 0.020 |
Why?
| | Cells, Cultured | 1 | 1996 | 4048 | 0.020 |
Why?
| | Cardiography, Impedance | 1 | 2007 | 8 | 0.020 |
Why?
| | Organ Size | 2 | 2005 | 446 | 0.020 |
Why?
| | Receptor, Endothelin B | 2 | 2000 | 55 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 987 | 0.020 |
Why?
| | Heart Rate, Fetal | 2 | 1999 | 20 | 0.020 |
Why?
| | Procollagen-Proline Dioxygenase | 1 | 2007 | 27 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 1990 | 642 | 0.020 |
Why?
| | Immediate-Early Proteins | 1 | 2007 | 58 | 0.020 |
Why?
| | Protein Precursors | 2 | 2000 | 126 | 0.020 |
Why?
| | Developmental Disabilities | 1 | 2009 | 254 | 0.020 |
Why?
| | Acute Kidney Injury | 1 | 2014 | 786 | 0.020 |
Why?
| | RNA, Viral | 1 | 1990 | 622 | 0.020 |
Why?
| | Proteins | 1 | 1992 | 945 | 0.020 |
Why?
| | Comorbidity | 1 | 2010 | 1542 | 0.020 |
Why?
| | Thoracic Diseases | 1 | 2005 | 13 | 0.020 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 1987 | 170 | 0.020 |
Why?
| | Respiratory Muscles | 1 | 2005 | 32 | 0.020 |
Why?
| | Oscillometry | 1 | 2005 | 37 | 0.020 |
Why?
| | Phosphates | 1 | 1986 | 168 | 0.020 |
Why?
| | Manometry | 1 | 2005 | 92 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2005 | 86 | 0.010 |
Why?
| | Hypertrophy | 1 | 2005 | 120 | 0.010 |
Why?
| | Colorado | 1 | 2015 | 4443 | 0.010 |
Why?
| | Muscular Diseases | 1 | 2005 | 110 | 0.010 |
Why?
| | Pulse Therapy, Drug | 1 | 2003 | 7 | 0.010 |
Why?
| | Drug Combinations | 1 | 2005 | 327 | 0.010 |
Why?
| | Research Design | 1 | 2010 | 1038 | 0.010 |
Why?
| | Time | 1 | 2003 | 75 | 0.010 |
Why?
| | Administration, Intranasal | 1 | 2003 | 84 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 2007 | 480 | 0.010 |
Why?
| | Pyrroles | 1 | 2004 | 201 | 0.010 |
Why?
| | Pharyngectomy | 1 | 2002 | 3 | 0.010 |
Why?
| | Hypopharyngeal Neoplasms | 1 | 2002 | 3 | 0.010 |
Why?
| | Speech, Alaryngeal | 1 | 2002 | 3 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 957 | 0.010 |
Why?
| | Receptor, Platelet-Derived Growth Factor beta | 1 | 2003 | 30 | 0.010 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2002 | 76 | 0.010 |
Why?
| | Laryngectomy | 1 | 2002 | 14 | 0.010 |
Why?
| | Clinical Competence | 1 | 2010 | 1020 | 0.010 |
Why?
| | Carrier Proteins | 1 | 1987 | 728 | 0.010 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2003 | 48 | 0.010 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2002 | 79 | 0.010 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2002 | 55 | 0.010 |
Why?
| | Nifedipine | 1 | 2002 | 28 | 0.010 |
Why?
| | Meclofenamic Acid | 1 | 2001 | 10 | 0.010 |
Why?
| | 8-Bromo Cyclic Adenosine Monophosphate | 1 | 2001 | 20 | 0.010 |
Why?
| | Oligonucleotides | 1 | 2002 | 140 | 0.010 |
Why?
| | Electrocardiography | 1 | 2005 | 602 | 0.010 |
Why?
| | Cyclooxygenase 1 | 1 | 2001 | 25 | 0.010 |
Why?
| | Infusions, Intra-Arterial | 1 | 2001 | 54 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2002 | 424 | 0.010 |
Why?
| | Glucocorticoids | 1 | 1986 | 570 | 0.010 |
Why?
| | Lymph Node Excision | 1 | 2002 | 166 | 0.010 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2001 | 67 | 0.010 |
Why?
| | Amidines | 1 | 2001 | 16 | 0.010 |
Why?
| | Benzylamines | 1 | 2001 | 42 | 0.010 |
Why?
| | Esophagectomy | 1 | 2002 | 122 | 0.010 |
Why?
| | Calcium Channel Blockers | 1 | 2002 | 125 | 0.010 |
Why?
| | Indoles | 1 | 2004 | 378 | 0.010 |
Why?
| | Pulmonary Ventilation | 1 | 2001 | 77 | 0.010 |
Why?
| | Calcium Channels | 1 | 2002 | 148 | 0.010 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2001 | 131 | 0.010 |
Why?
| | Cyclooxygenase 2 | 1 | 2001 | 172 | 0.010 |
Why?
| | Ligands | 1 | 2003 | 614 | 0.010 |
Why?
| | Organ Specificity | 1 | 2001 | 296 | 0.010 |
Why?
| | Drug Interactions | 1 | 2001 | 370 | 0.010 |
Why?
| | Calcium | 1 | 1986 | 1173 | 0.010 |
Why?
| | Physical Stimulation | 1 | 2000 | 74 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2005 | 2308 | 0.010 |
Why?
| | Lung Volume Measurements | 1 | 1999 | 44 | 0.010 |
Why?
| | Charybdotoxin | 1 | 1999 | 6 | 0.010 |
Why?
| | Lung Diseases, Interstitial | 1 | 2005 | 594 | 0.010 |
Why?
| | Atrial Function, Right | 1 | 1998 | 12 | 0.010 |
Why?
| | Delayed Rectifier Potassium Channels | 1 | 1998 | 10 | 0.010 |
Why?
| | Shab Potassium Channels | 1 | 1998 | 19 | 0.010 |
Why?
| | Digestive System | 1 | 1998 | 29 | 0.010 |
Why?
| | Electric Conductivity | 1 | 1998 | 94 | 0.010 |
Why?
| | Isothiuronium | 1 | 1998 | 3 | 0.010 |
Why?
| | Xenopus | 1 | 1998 | 84 | 0.010 |
Why?
| | Thiazines | 1 | 1998 | 9 | 0.010 |
Why?
| | Long-Term Care | 1 | 1998 | 88 | 0.010 |
Why?
| | Masks | 1 | 1998 | 59 | 0.010 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2002 | 816 | 0.010 |
Why?
| | DNA, Complementary | 1 | 1998 | 270 | 0.010 |
Why?
| | Quality of Life | 1 | 2009 | 2706 | 0.010 |
Why?
| | Catheterization | 1 | 1998 | 176 | 0.010 |
Why?
| | Gene Expression | 1 | 2003 | 1476 | 0.010 |
Why?
| | Medical Records | 1 | 1998 | 170 | 0.010 |
Why?
| | Oocytes | 1 | 1998 | 178 | 0.010 |
Why?
| | Dogs | 1 | 1998 | 372 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 1998 | 536 | 0.010 |
Why?
| | Methylene Blue | 1 | 1996 | 24 | 0.010 |
Why?
| | Indomethacin | 1 | 1996 | 78 | 0.010 |
Why?
| | Microvilli | 2 | 1987 | 75 | 0.010 |
Why?
| | Adenosine | 1 | 1998 | 213 | 0.010 |
Why?
| | Staining and Labeling | 1 | 1996 | 142 | 0.010 |
Why?
| | Carcinoma, Papillary, Follicular | 1 | 1995 | 8 | 0.010 |
Why?
| | Cardiomegaly | 1 | 1997 | 172 | 0.010 |
Why?
| | Purinones | 1 | 1995 | 4 | 0.010 |
Why?
| | Purinergic P1 Receptor Antagonists | 1 | 1995 | 8 | 0.010 |
Why?
| | Receptors, Purinergic P1 | 1 | 1995 | 24 | 0.010 |
Why?
| | Adenocarcinoma, Follicular | 1 | 1995 | 34 | 0.010 |
Why?
| | Sodium | 2 | 1987 | 203 | 0.010 |
Why?
| | Arterioles | 1 | 1995 | 42 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 1999 | 1504 | 0.010 |
Why?
| | Theophylline | 1 | 1995 | 66 | 0.010 |
Why?
| | Carcinoma, Papillary | 1 | 1995 | 77 | 0.010 |
Why?
| | Home Care Services | 1 | 1998 | 246 | 0.010 |
Why?
| | Neurotransmitter Agents | 1 | 1995 | 82 | 0.010 |
Why?
| | Phenylephrine | 1 | 1995 | 75 | 0.010 |
Why?
| | Renal Circulation | 1 | 1995 | 57 | 0.010 |
Why?
| | Adrenal Glands | 1 | 1995 | 72 | 0.010 |
Why?
| | Viper Venoms | 1 | 1994 | 9 | 0.010 |
Why?
| | Muscle Tonus | 1 | 1994 | 19 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1998 | 2047 | 0.010 |
Why?
| | Neoplasm Invasiveness | 1 | 1995 | 479 | 0.010 |
Why?
| | Forecasting | 1 | 1995 | 363 | 0.010 |
Why?
| | Cause of Death | 1 | 1995 | 392 | 0.010 |
Why?
| | Perfusion | 1 | 1994 | 191 | 0.010 |
Why?
| | Intestines | 1 | 1995 | 346 | 0.010 |
Why?
| | Extracellular Matrix | 1 | 1995 | 493 | 0.010 |
Why?
| | Chemotaxis | 1 | 1991 | 130 | 0.010 |
Why?
| | Macrophage Activation | 1 | 1991 | 178 | 0.010 |
Why?
| | Electrophoresis, Agar Gel | 1 | 1990 | 26 | 0.010 |
Why?
| | Agammaglobulinemia | 1 | 1990 | 34 | 0.010 |
Why?
| | Nucleic Acid Hybridization | 1 | 1990 | 191 | 0.010 |
Why?
| | Gene Amplification | 1 | 1990 | 102 | 0.010 |
Why?
| | Cell Count | 1 | 1990 | 316 | 0.000 |
Why?
| | Myocardial Contraction | 1 | 1990 | 336 | 0.000 |
Why?
| | Adenocarcinoma | 1 | 1995 | 895 | 0.000 |
Why?
| | Eosinophils | 1 | 1990 | 324 | 0.000 |
Why?
| | Kidney Cortex | 1 | 1987 | 25 | 0.000 |
Why?
| | Polymerase Chain Reaction | 1 | 1990 | 1045 | 0.000 |
Why?
| | Sodium-Hydrogen Exchangers | 1 | 1987 | 24 | 0.000 |
Why?
| | Monocytes | 1 | 1990 | 553 | 0.000 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1987 | 542 | 0.000 |
Why?
| | Skin | 1 | 1990 | 737 | 0.000 |
Why?
| | Glomerular Filtration Rate | 1 | 1987 | 684 | 0.000 |
Why?
| | Macrophages | 1 | 1990 | 1452 | 0.000 |
Why?
|
|
Kinsella's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|